SV

Street Verdict

Analyst Scorecard

ERIS · NSE

Eris Lifesciences Limited

₹1,317.2

-0.89% (-₹11.8)

Prev. close

₹1,329

Volume

33,292

Delivery %

32.9%

As of

20 Nov 2026

Price history

₹1,317.2-₹32.9 (-2.44%) · 3M
18 Aug 2026 → 20 Nov 2026
1,1001,1501,2001,2501,3001,35018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Eris Lifesciences Limited

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, GLP-1, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram monitoring, continuous glucose monitoring system, sleep device, antenatal care, and early neuropathy screening solutions, as well as polycystic ovary syndrome screening, diagnosis, and management. The company offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Amit Indubhushan Bakshi

Headquarters

Ahmedabad

Employees

2,758

Website

eris.co.in

Key stats

Market cap

₹16,654.18 Cr

P/E ratio (TTM)

23.7

Dividend yield

1.22%

EPS (TTM)

₹50.66

Beta (1Y · daily vs NIFTY 50)

0.55

Beta (5Y · monthly vs NIFTY 50)

0.70

Shares float

4.43 Cr

EPS · quarter ended Sept 2026

₹13.25

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0%10%20%30%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0204060₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0358₹-100%-50%0%50%100%19 Mar 2013 Aug 2005 Aug 2111 Aug 2213 Feb 2529 May 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr2500 Cr5000 Cr7500 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr2500 Cr5000 Cr7500 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-2000 Cr0 Cr2000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,211.86 Cr₹1,347.04 Cr₹1,685.15 Cr₹2,009.14 Cr₹2,893.64 Cr₹3,129.42 Cr
EBITDA
₹439.28 Cr₹511.05 Cr₹547.90 Cr₹698.65 Cr₹1,035.56 Cr₹1,110.62 Cr
₹355.14 Cr₹406.11 Cr₹382.16 Cr₹391.98 Cr₹351.84 Cr₹619.52 Cr
Diluted EPS
₹26.14₹29.88₹28.07₹28.79₹25.81₹45.26

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,834.78 Cr₹2,272.14 Cr₹3,667.33 Cr₹7,048.84 Cr₹7,033.17 Cr₹7,365.51 Cr
₹6.78 Cr₹84.41 Cr₹876.71 Cr₹2,781.28 Cr₹2,477.92 Cr₹2,358.62 Cr
Stockholders' equity
₹1,577.00 Cr₹1,909.00 Cr₹2,196.00 Cr₹2,587.00 Cr₹2,855.00 Cr₹3,903.00 Cr

CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹375.00 Cr₹378.00 Cr₹292.00 Cr₹486.00 Cr₹1,065.00 Cr₹538.00 Cr
Investing cash flow
₹-323.36 Cr₹-319.61 Cr₹-974.61 Cr₹-1,854.52 Cr₹-79.97 Cr₹-369.46 Cr
₹-82.00 Cr₹-45.00 Cr₹688.00 Cr₹1,380.00 Cr₹-881.00 Cr₹-314.00 Cr
Capital expenditure
₹-26.00 Cr₹-121.00 Cr₹-841.00 Cr₹-129.00 Cr₹-155.00 Cr₹-297.00 Cr
End cash position
₹36.92 Cr₹50.87 Cr₹56.02 Cr₹94.25 Cr₹199.74 Cr₹54.74 Cr

Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemJun 17–Jun 18(6Q)Sep 18Dec 18Mar 19Jun 19–Dec 19(3Q)Mar 20–Jun 20(2Q)Sep 20Dec 20Mar 21Jun 21Sep 21Dec 21–Mar 22(2Q)Jun 22Sep 22Dec 22Mar 23–Jun 23(2Q)Sep 23Dec 23–Mar 24(2Q)Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25–Dec 25(2Q)Mar 26Jun 26
Promoter55.93%55.92%56.04%56.10%56.23%55.55%54.08%54.23%54.13%52.69%52.68%52.66%52.30%52.29%52.70%52.86%54.91%54.90%54.88%54.87%54.86%54.85%54.83%54.85%53.92%54.14%
Public44.07%44.08%43.96%43.90%43.77%44.45%45.92%45.77%45.87%47.31%47.32%47.34%47.70%47.71%47.30%47.14%45.09%45.10%45.12%45.13%45.14%45.15%45.17%45.15%46.08%45.86%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Eris Lifesciences Limited₹16,654.18 Cr₹1,21523.74.2715.9%0.60+8.2%-24.1%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

2 indices

ERIS

Eris Lifesciences expects 150-200 bps margin improvement in H2 as biologics scale up

CNBC TV18 · 26 days ago

ERIS

Eris Lifesciences Files Scrutinizer’s Report and Voting Results for 20th AGM

Eris Lifesciences Ltd submitted the scrutinizer’s report and voting results for its 20th Annual General Meeting, held on September 25, 2026. Shareholders participated through remote e-voting and electronic voting. This action reflects the company's compliance with corporate governance and regulatory requirements.

2 months ago·Read at TipRanks